Detailed information is available for translational, development and access projects (click on the boxes below).
Download the MMV-supported projects slide, 4Q 2016 [3Mb]
Download the Global Portfolio of Antimalarial Medicines slide, 4Q 2016 [3Mb]
For more information about the global malaria portfolio, read the article: Malaria medicines: a glass half full?
Global Fund Expert Review Panel (ERP) reviewed product - permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing.
Included in MMV portfolio after product approval.
WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers.
* A single dose of 500/25mg SP on Day 1. 150mg AQ given once daily on Day 1, 2 and 3.
** A single dose of 250/12.5mg SP on Day 1. 75mg AQ given once daily on Day 1, 2, and 3.
1 Coartem® Dispersible
2 Artesun®
3 Eurartesim®
4 Pyramax® tablets or granules
5 ASAQ Winthrop®
6 SPAQ-COTM
____ 3-day cure, artemisinin-based combination therapies
____ Combinations aiming at a new Single exposure radical cure
____ Severe malaria and pre-referral treatment
____ Intermittent/Seasonal Malaria Chemoprevention
____ Products targeting prevention of relapse for P. vivax
Asexual blood stages
Relapse prevention
Transmission reduction
Chemoprevention